Neurotensin Receptor Ligands
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,961,199 | Neurotensin Receptor Ligands In force · High confidence UsedRemaining | 3B Pharmaceuticals GmbH | In force | High confidence | ||
| Application 17/112,258 | Neurotensin Receptor Ligands Abandoned Abandoned Jul 29, 2025 | 3B Pharmaceuticals GmbH | Abandoned | Abandoned Jul 29, 2025 | ||
| Application 19/222,493 | Neurotensin Receptor Ligands Pending Not granted | 3B Pharmaceuticals GmbH | Pending | Not granted |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by 3B Pharmaceuticals GmbH.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.